| Tammy L Skidmore, CRNA | |
|
777 Hospital Way, Pocatello, ID 83201-5175 | |
| (208) 239-1000 | |
| Not Available |
| Full Name | Tammy L Skidmore |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 21 Years |
| Location | 777 Hospital Way, Pocatello, Idaho |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427008176 | NPI | - | NPPES |
| 806817800 | Medicaid | ID | |
| 145477 | Other | KS | BCBS KS GROUP 110017 |
| 200429720A | Medicaid | KS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | N27623 (Idaho) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | RNA-582 (Idaho) | Primary |
| Entity Name | Overton/stiff Professional Anesthesia Service Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417065152 PECOS PAC ID: 6901793975 Enrollment ID: O20040507001312 |
News Archive
The rate of growth on premiums for employer-based health coverage in the first five months of this year was one of the lowest in 16 years. Despite longstanding concerns that employer-sponsored coverage might become too costly to sustain, that market seems to have stabilized for now .... Thanks to the Affordable Care Act, federal tax credit subsidies -; available for people earning up to 400 percent of the federal poverty level ($95,400 for a family of four) -; are helping to make these policies affordable and cushioning the impact of premium increases in some cities (9/14).
Nanostics Inc. announced today that from the launch of its clinical validation study for ClarityDX Prostate, recruitment of men increased significantly in November, pushing the number of men enrolled over 200.
Among the 118 patients with portal vein thrombosis, noncirrhotic and nontumoral extrahepatic portal vein obstruction are young and present with well tolerated bleed.
Chiasma, Inc., a privately held biopharma company, announced today that it has granted Novartis an option to obtain exclusive worldwide rights to develop and commercialize the Company's Transient Permeability Enhancer (TPE) technology for use with certain related small molecule products either in development or currently marketed by Novartis.
Repros Therapeutics Inc. today announced that the Company has received positive written feedback from the FDA (the "Agency") regarding the Company's drug candidate Androxal. The Agency concurred with Repros' indication statement for the use of Androxal in the treatment of secondary hypogonadism in men wishing to preserve fertility.
› Verified 6 days ago
| Entity Name | Treasure Valley Anesthesia Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215992003 PECOS PAC ID: 2365414497 Enrollment ID: O20121213000463 |
News Archive
The rate of growth on premiums for employer-based health coverage in the first five months of this year was one of the lowest in 16 years. Despite longstanding concerns that employer-sponsored coverage might become too costly to sustain, that market seems to have stabilized for now .... Thanks to the Affordable Care Act, federal tax credit subsidies -; available for people earning up to 400 percent of the federal poverty level ($95,400 for a family of four) -; are helping to make these policies affordable and cushioning the impact of premium increases in some cities (9/14).
Nanostics Inc. announced today that from the launch of its clinical validation study for ClarityDX Prostate, recruitment of men increased significantly in November, pushing the number of men enrolled over 200.
Among the 118 patients with portal vein thrombosis, noncirrhotic and nontumoral extrahepatic portal vein obstruction are young and present with well tolerated bleed.
Chiasma, Inc., a privately held biopharma company, announced today that it has granted Novartis an option to obtain exclusive worldwide rights to develop and commercialize the Company's Transient Permeability Enhancer (TPE) technology for use with certain related small molecule products either in development or currently marketed by Novartis.
Repros Therapeutics Inc. today announced that the Company has received positive written feedback from the FDA (the "Agency") regarding the Company's drug candidate Androxal. The Agency concurred with Repros' indication statement for the use of Androxal in the treatment of secondary hypogonadism in men wishing to preserve fertility.
› Verified 6 days ago
| Entity Name | T-medica Mobil Anesthesia Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306588355 PECOS PAC ID: 9931588498 Enrollment ID: O20220614001826 |
News Archive
The rate of growth on premiums for employer-based health coverage in the first five months of this year was one of the lowest in 16 years. Despite longstanding concerns that employer-sponsored coverage might become too costly to sustain, that market seems to have stabilized for now .... Thanks to the Affordable Care Act, federal tax credit subsidies -; available for people earning up to 400 percent of the federal poverty level ($95,400 for a family of four) -; are helping to make these policies affordable and cushioning the impact of premium increases in some cities (9/14).
Nanostics Inc. announced today that from the launch of its clinical validation study for ClarityDX Prostate, recruitment of men increased significantly in November, pushing the number of men enrolled over 200.
Among the 118 patients with portal vein thrombosis, noncirrhotic and nontumoral extrahepatic portal vein obstruction are young and present with well tolerated bleed.
Chiasma, Inc., a privately held biopharma company, announced today that it has granted Novartis an option to obtain exclusive worldwide rights to develop and commercialize the Company's Transient Permeability Enhancer (TPE) technology for use with certain related small molecule products either in development or currently marketed by Novartis.
Repros Therapeutics Inc. today announced that the Company has received positive written feedback from the FDA (the "Agency") regarding the Company's drug candidate Androxal. The Agency concurred with Repros' indication statement for the use of Androxal in the treatment of secondary hypogonadism in men wishing to preserve fertility.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tammy L Skidmore, CRNA Po Box 4107, Pocatello, ID 83205-4107 Ph: (208) 232-7760 | Tammy L Skidmore, CRNA 777 Hospital Way, Pocatello, ID 83201-5175 Ph: (208) 239-1000 |
News Archive
The rate of growth on premiums for employer-based health coverage in the first five months of this year was one of the lowest in 16 years. Despite longstanding concerns that employer-sponsored coverage might become too costly to sustain, that market seems to have stabilized for now .... Thanks to the Affordable Care Act, federal tax credit subsidies -; available for people earning up to 400 percent of the federal poverty level ($95,400 for a family of four) -; are helping to make these policies affordable and cushioning the impact of premium increases in some cities (9/14).
Nanostics Inc. announced today that from the launch of its clinical validation study for ClarityDX Prostate, recruitment of men increased significantly in November, pushing the number of men enrolled over 200.
Among the 118 patients with portal vein thrombosis, noncirrhotic and nontumoral extrahepatic portal vein obstruction are young and present with well tolerated bleed.
Chiasma, Inc., a privately held biopharma company, announced today that it has granted Novartis an option to obtain exclusive worldwide rights to develop and commercialize the Company's Transient Permeability Enhancer (TPE) technology for use with certain related small molecule products either in development or currently marketed by Novartis.
Repros Therapeutics Inc. today announced that the Company has received positive written feedback from the FDA (the "Agency") regarding the Company's drug candidate Androxal. The Agency concurred with Repros' indication statement for the use of Androxal in the treatment of secondary hypogonadism in men wishing to preserve fertility.
› Verified 6 days ago
Mr. Timothy Morgan Naylor, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 285 Vista Dr, Pocatello, ID 83201 Phone: 208-478-1704 | |
Nicholas Stoddard, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 777 Hospital Way, Pocatello, ID 83201 Phone: 208-232-7760 Fax: 208-232-1950 | |
Mark Alan Pendleton, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 777 Hospital Way, Pocatello, ID 83201 Phone: 082-391-0562 Fax: 208-239-3626 | |
Jamie Leigh Cassinat, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 777 Hospital Way, Pocatello, ID 83201 Phone: 208-209-1000 | |
Eric Michael Stradley, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 777 Hospital Way, Pocatello, ID 83201 Phone: 208-239-1000 | |
Richard Aaron Marler, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 333 N 18th Ave, Bldg A, Pocatello, ID 83201 Phone: 208-233-8880 Fax: 208-232-1950 | |
Mr. Kenneth Michael Knapp, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 333 N 18th Ave Ste A, Pocatello, ID 83201 Phone: 208-232-7760 Fax: 208-232-1950 |